Validation of the Decision model of the Burden of Hearing loss Across the Lifespan (DeciBHAL) in Chile, India, and Nigeria

Ethan D. Borre, Austin Ayer, Carolina Der, Titus Ibeke, Susan D. Emmett, Siddharth Dixit, Minahil Shahid, Bolajoko Olusanya, Suneela Garg, Mohini John, James E. Saunders, Debora L. Tucci, Blake S. Wilson, Osondu Ogbuoji, and Gillian D. Sanders Schmidler

Summary

Background

There is no published decision model for informing hearing health care resource allocation across the lifespan in low- and middle-income countries. We sought to validate the Decision model of the Burden of Hearing loss Across the Lifespan International (DeciBHAL-I) in Chile, India, and Nigeria.

Methods

DeciBHAL-I simulates bilateral sensorineural hearing loss (SNHL) and conductive hearing loss (CHL) acquisition, SNHL progression, and hearing loss treatment. To inform model inputs, we identified setting-specific estimates including SNHL prevalence from the Global Burden of Disease (GBD) studies, acute otitis media (AOM) incidence and prevalence of otitis-media related CHL from a systematic review, and setting-specific pediatric and adult hearing aid use prevalence. We considered a coefficient of variance root mean square error (CV-RMSE) of $\leq 15\%$ to indicate good model fit.

Findings

The model-estimated prevalence of bilateral SNHL closely matched GBD estimates, (CV-RMSEs: 3.2-7.4%). Age-specific AOM incidences from DeciBHAL-I also achieved good fit (CV-RMSEs=5.0-7.5%). Model-projected chronic suppurrative otitis media prevalence (1.5% in Chile, 4.9% in India, and 3.4% in Nigeria) was consistent with setting-specific estimates, and the incidence of otitis media-related CHL was calibrated to attain adequate model fit. DeciBHAL-projected adult hearing aid use in Chile (3.2-19.7% ages 65-85 years) was within the 95% confidence intervals of published estimates. Adult hearing aid prevalence from the model in India was 1.4-2.3%, and 1.1-1.3% in Nigeria, consistent with literature-based and expert estimates.

Interpretation

DeciBHAL-I reasonably simulates hearing loss natural history, detection, and treatment in Chile, India, and Nigeria. Future cost-effectiveness analyses might use DeciBHAL-I to inform global hearing health policy.

Funding

National Institutes of Health (3UL1-TR002553-03S3 and F30 DC019846).

Copyright © 2022 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Keywords: Hearing loss; Decision modeling; Global health policy
Research in context

Evidence before this study

In a previously published systematic review, we searched MEDLINE on 14 June 2020 using the search string: (“Hearing Loss”[Mesh] OR “hearing”[tiab]) AND (“Costs and Cost Analysis”[Mesh] OR “Cost-Benefit Analysis”[Mesh] OR “cost-benefit”[tiab] OR “cost-effectiveness”[tiab] OR “costutility”[tiab] OR “economic evaluation”[tiab] OR “economic evaluations”[tiab] OR “economic model”[tiab] OR “economic models”[tiab]) AND English[lang] AND (NOT(“Editorial”[ptyp] OR “Letter”[ptyp] OR “Case Report”[ptyp] OR “Comment”[ptyp]) NOT (animals[mh] NOT humans[mh])). We extended the search to EMBASE, Cochrane Library, and Global Index Medicus. This review identified few published decision models that addressed in low- and middle-income settings, and none that considered multiple interventions across the lifespan.

Added value of this study

This study sought to extend Decision model of the Burden of Hearing loss Across the Lifespan (DeciBHAL), previously validated in the United States, to three international settings: Chile, India, and Nigeria. DeciBHAL is a Markov microsimulation model of the prevention, natural history, diagnosis, and treatment of hearing loss. This study provides the first validated decision modeling framework of hearing loss across the lifespan in these settings.

Implications of all the available evidence

Our modeling framework, input with setting-specific cost and utility data, may be used to inform decisions around scarce resource allocation to hearing healthcare. DeciBHAL allows for comparison of hearing healthcare interventions at multiple points in the lifespan, and across different points in the care cascade, from prevention of hearing loss to diagnosis to retention on effective therapy. In conjunction with the Lancet Commission on Hearing Loss, planned cost-effectiveness analyses may guide policy conversations in global hearing health.

Methods

Analytic overview

Our objective was to validate DeciBHAL-I, a decision model of hearing loss across the lifespan in Chile, India, and Nigeria. To develop the DeciBHAL International (DeciBHAL-I) model versions, we consulted with hearing loss clinical experts in Chile, India, and Nigeria, and with experts in the Lancet Commission on Hearing Loss. In choosing DeciBHAL-I settings, all countries with stakeholder representation on the Lancet Commission were considered. The final settings were chosen based on data availability and to ensure differences in geography, income level, and hearing loss epidemiology to better inform global hearing health policy in future analyses. We first discussed key model structure and input data within DeciBHAL that would need adjusting to better simulate hearing loss prevention, natural history, detection, diagnosis and treatment in Chile, India, and Nigeria. Our discussions consisted of teleconferences and email correspondence with hearing healthcare experts in our target settings (including co-authors CD, TI, BO, and SG). We followed the Assessment of the Validation Status of Health-Economic decision models (AdVISHE) framework, and following this model our discussions with collaborators consisted of questions...
regarding the face validity of the model structure, identification of input data, and validity of model-projected results.\textsuperscript{9} We then used a previously published method for validating DeciBHAL in the US to validate our model-projected outputs to external estimates across the natural histories of sensorineural hearing loss (SNHL) and conductive hearing loss (CHL), and the hearing loss cascade of care.\textsuperscript{9} Throughout the subsequent narrative model description, we delineate key modeling assumptions.

**Model overview and hearing loss health states**

DeciBHAL-I is a microsimulation model, parameterized with input data from the published literature, and implemented in TreeAge software (Williamstown, MA).\textsuperscript{2} Briefly, health states within the model are determined by: 1) the presence of hearing loss, 2) hearing loss type (SNHL, CHL, chronic suppurative otitis media (CSOM)-associated CHL), and 3) treatment modality if applicable. The full model structure is graphically represented in Appendix 1. Consistent with the Global Burden of Disease (GBD) studies and World Health Organization (WHO), DeciBHAL-I hearing loss severity is categorized based on the pure tone average (PTA) of auditory thresholds at 500, 1,000, 2,000, and 4,000 hertz in the better-hearing ear: 20-34 decibels (dB) is mild, 35-49 dB is moderate, 50-64 dB is moderately severe, 65-79 dB is severe, 80-94 dB is profound, and 95+ dB is complete hearing loss.\textsuperscript{2,10} In the model, simulated persons are assigned demographic characteristics and each year undergo setting-specific probabilities of acquiring hearing loss, progression of existing hearing loss, and treatment uptake or discontinuation. We incorporated age- and sex-specific mortality rates from the WHO and United Nations Population Division.\textsuperscript{11,12} The presence and severity of SNHL and CHL are tracked for each simulated person independently in PTA thresholds and health state utility is dependent on the more severe of the two.

**Incidence of SNHL**

We used GBD 2019 estimates\textsuperscript{15} of age- and sex-specific prevalence of hearing loss in Chile, India, and Nigeria, combined with life-table data, to derive incidence of hearing loss (Table 1).\textsuperscript{10} For SNHL, we used the GBD categorization of age-related and other hearing loss. DeciBHAL-I simulates only bilateral SNHL to remain consistent with the input data. Model-projected SNHL prevalence was then compared to GBD estimates in an internal validation exercise.

**Cause-specific SNHL**

We assumed SNHL was due to one of three etiologies: 1) meningitis, 2) ototoxicity, or 3) age-related and additional causes other than meningitis or ototoxicity (referred to as “age-related and other causes” throughout this report; CHL is discussed distinctly below). While age-related and other SNHL accounts for substantially more hearing loss prevalence than the other two etiologies, we included meningitis-related and ototoxic SNHL in the model structure due to the potential for prevention of these types of hearing loss through vaccination programs or reduction in ototoxic medication use. We ensured use of epidemiologic estimates that accounted for the differential contributions of these etiologies to total hearing loss prevalence. We estimated the age-specific proportion of SNHL due to meningitis by adjusting data on setting- and age-specific meningitis incidences, case-fatality rates, and probabilities of hearing loss after meningitis (Table 1).\textsuperscript{14-18} For ototoxicity, we newly developed model structure to consider aminoglycoside treatment for multi-drug resistant tuberculosis (MDR-TB) and platinum-based chemotherapeutics (cisplatin and carboplatin) as contributors to hearing loss (Appendix 1). However, we did not utilize this model structure in the current validation exercises due to current data limitations. This exclusion did not affect any validations presented herein and ongoing efforts may provide the necessary data to inform this DeciBHAL-I sub-module. Previously published estimates of the yearly number of new hearing loss cases due to MDR-TB treatment may be incorporated as a proportion of hearing loss at each age.\textsuperscript{19} All other sensorineural hearing loss was assumed to be age-related, and we assumed that simulated persons can only experience one cause of SNHL throughout their lifetime.

**SNHL progression**

After acquiring SNHL of any cause, simulated persons are assigned an etiology-specific SNHL PTA severity (in dB) based on the average hearing loss PTA for each etiology (Table 1).\textsuperscript{18,20,21} We assigned a PTA severity of 25 dB HL for all persons upon acquiring age-related and other SNHL. We used US-based estimates of the yearly age-specific decline in hearing for persons age 35+, defined as a mean 1.05dB/year (SD=0.4) PTA increase in dB HL.\textsuperscript{22-24} We included a model input to allow for calibration of SNHL progression to better match external data sources such as the GBD.\textsuperscript{25}

**Natural history of otitis media-related and other CHL**

As described previously, DeciBHAL simulates acute otitis media (AOM), otitis media with effusion (OME), and chronic suppurative otitis media (CSOM) as distinct CHL etiologies, and simulates all other causes of CHL in aggregate.\textsuperscript{3} Yearly AOM incidence for each setting was derived from a systematic review, and 17% of AOM cases persisted for greater than 1 year.\textsuperscript{24-25} OME was simulated as a sequel of AOM after resolution, or spontaneously. Yearly rates of spontaneous (non-AOM-
Variable | Chile | India | Nigeria | Reference
--- | --- | --- | --- | ---
**Bilateral SNHL probability, yearly, %**
| | Males | Females | Males | Females | Males | Females |
|---|---|---|---|---|---|---|
| Age 0y | 0.12 | 0.08 | 0.16 | 0.14 | 0.46 | 0.48 |
| Ages 1-3y | 0.15 | 0.11 | 0.31 | 0.28 | 0.53 | 0.66 |
| Ages 4-7y | 0.13 | 0.11 | 0.30 | 0.26 | 0.56 | 0.57 |
| Ages 8-12y | 0.07 | 0.06 | 0.18 | 0.16 | 0.19 | 0.16 |
| Ages 13-17y | 0.13 | 0.12 | 0.23 | 0.22 | 0.11 | 0.13 |
| Ages 18-22y | 0.35 | 0.24 | 0.65 | 0.57 | 0.52 | 0.46 |
| Ages 28-37y | 0.44 | 0.29 | 0.76 | 0.66 | 0.73 | 0.55 |
| Ages 38-47y | 0.79 | 0.45 | 1.86 | 1.75 | 1.02 | 0.85 |
| Ages 48-57y | 2.47 | 1.46 | 3.23 | 2.99 | 2.15 | 1.89 |
| Ages 58-67y | 4.16 | 3.17 | 3.31 | 3.17 | 2.65 | 2.03 |
| Ages 68-77y | 5.61 | 4.76 | 4.46 | 4.17 | 2.50 | 2.30 |
| Ages 78+y | 7.00 | 6.22 | 5.50 | 4.91 | 1.30 | 1.19 |

**SNHL Severity, PTA, by etiology**
Meningitis (dB) | 68
Ototoxicity (dB) | 39

**SNHL Progression, PTA decline in dB, mean (SD)**
All ages | 1.05 (0.4)

**AOM Probability, yearly**
| Age (y) | 0.5 | 2 | 7 | 12 | 17 | 22 | 30 | 40 | 50 | 60 | 70 | 80 | 90 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|  | 7.75 | 8.72 | 3.75 | 1.54 | 1.63 | 1.6 | 0.89 | 0.89 | 1.05 | 1.14 | 1.27 | 1.44 | 1.39 |
|  | 15.80 | 21.31 | 8.53 | 7.92 | 4.24 | 3.79 | 1.92 | 1.93 | 2.32 | 2.52 | 2.8 | 3.18 | 3.06 |
|  | 30.43 | 42.33 | 17.76 | 19.86 | 9.39 | 8.12 | 4.05 | 4.10 | 4.98 | 5.37 | 5.97 | 6.83 | 6.82 |

Probability of Recurrent AOM after AOM, % | 17.0

Probability of OME ≥3 months after AOM, % | 26.0

Probability of OME resolution after OME ≥3 month onset, % yearly
| Year | 1 | 2 | 3 |
|---|---|---|---|
|  | 70.5 | 25.0 | 25.0 |

Hearing loss, PTA, during CSOM, dB, mean | 34.2

Hearing loss, PTA, after CSOM, dB, mean (SD) | 17.0 (18.6)

Table 1 (Continued)
related) OME were derived using data from the Netherlands given lack of setting-specific data for the target countries.26,27

Simulated persons who experience recurrent AOM, or OME persisting ≥ 1 year, enter a distinct health state (recurrent AOM/persistent OME) during the subsequent model cycle. In this health state (average duration 2 years), patients are subject to annual age- and setting-specific probabilities of developing CSOM.24 We calibrated the average duration of CSOM to setting-specific estimates of the prevalence of CSOM (1.2% in Chile, 7.8% in India, and 3.6% in Nigeria).28 During active disease, CSOM causes CHL with an assumed PTA of 34 dB HL. Following CSOM resolution, a proportion of simulated persons experience residual CHL (Mean=17 dB air conduction threshold, SD=18.6 dB).29,30 The probability of residual CHL after CSOM was calibrated to literature-derived estimates.24 Given data limitations, we used US data to derive the yearly probability of permanent CHL not due to CSOM, with average PTA assumed to be 40 dB HL.31

**Mixed hearing loss**

In DeciBHAL, simulated persons may acquire both SNHL and CHL according to age- and sex-specific incidences. Given data limitations, we assumed independence between SNHL and CHL despite emerging evidence associating SNHL and CHL.30,32 The model tracks the severity of hearing loss due to SNHL and CHL independently, and severity-dependent parameters are dependent on the more severe PTA.

**Hearing loss cascade of care**

We derived probabilities of hearing aid uptake in Chile, India, and Nigeria from the published literature where available. In Chile, we used data on the number of hearing aids distributed by the national health program to adults age >65 years in 2016, and the number of persons with untreated hearing loss, to derive a yearly probability of hearing aid provision.10,33 We used Chilean estimates of the prevalence of hearing aid use by age and severity to derive age- and severity-specific yearly uptake probabilities.34 Lastly, we incorporated a delay-to-diagnosis factor into our uptake rates to better match input data.34 A National Disability in India household survey reported that 19.1% of adults with a hearing disability used a hearing aid.35 Because this data was self-reported and underestimated the prevalence of hearing loss by a factor of 10 compared to a high-quality audiometric study in India,36 we applied a multiplier of 0.10, representing the probability of hearing loss diagnosis. This yielded a hearing aid prevalence

| Variable | Chile | India | Nigeria | Reference |
|----------|-------|-------|---------|-----------|
| Yearly probability of HA uptake, %<sup>a</sup> | PTA < 40 dB | PTA ≥ 40 dB | PTA < 40 dB | PTA ≥ 40 dB | PTA < 40 dB | PTA ≥ 40 dB |
| Age 0y | 58.1 | 58.1 | 1.5 | 1.5 | 2.5 | 2.5 |
| Ages 1-5y | 1.6 | 1.6 | 1.25 | 1.25 | 1.75 | 1.75 |
| Ages 19-55y | 0.1 | 0.1 | 0.4 | 0.4 | 1.5 | 1.5 |
| Age 65y<sup>a</sup> | 0.1 | 0.1 | 0.04 | 0.04 | 0.2 | 0.2 |
| Age 75y<sup>a</sup> | 0.2 | 0.2 | 0.06 | 0.06 | 0.2 | 0.2 |
| Age 85y<sup>a</sup> | 0.4 | 0.4 | 0.06 | 0.06 | 0.2 | 0.2 |

| Yearly probability of HA d/c, %, ages 1-18 years | 3.0 |
| Yearly probability of HA d/c, ages 18+, range 1-10+ years after use | 3.5-12.9% |
| Yearly probability of CI implantation, % | Adults with severe+ HL with hearing aid, % | 0.5 | 0.1 | 0.01 |
| Children with severe+ HL with hearing aid, % | 18.6 | 0.1 | 0.01 |

**Table 1**: Selected model input data.

Abbreviations: AOM: acute otitis media; CHL: conductive hearing loss; CI: cochlear implant; CSOM: chronic suppurative otitis media; dB: decibel; d/c: discontinuation; HA: hearing aid; HL: hearing loss; OME: otitis media with effusion; PTA: pure tone average; SD: standard deviation; SNHL: sensorineural hearing loss; y: year.

<sup>a</sup> Linear interpolation was used between ages not displayed.

<sup>b</sup> In Chile, the yearly probability of hearing aid uptake changed at ages 60, 70, and 80 years to better match input data.
calibration target of 1.91%. A sensitivity analysis was performed varying this multiplier from 0.1-1.0 (Appendix 2). Assuming this calibration target represented persons with 40 dB HL or greater hearing loss at a mean age of 75 years, and incorporating age- and severity-specific risk ratios of hearing aid ownership from China, we derived yearly probabilities of hearing aid uptake in India.30 We were unable to identify nationally representative data on adult hearing aid use in Nigeria. One study estimated that of 498 patients evaluated for hearing loss at an ear nose and throat clinic, 3 adults (1.4%) eventually procured hearing aids.38 Given evidence of low uptake, even among those with diagnosed hearing loss, we relied on expert opinion to assume that 0.5-1% of Nigerian adults with hearing loss used hearing aids at ages 65-85 years. Given a lack of setting-specific estimates of hearing aid discontinuation, we assumed the yearly probability of hearing aid discontinuation to be equivalent to that observed in the United States (4-13%/year).39,40

For pediatric hearing aid use in Chile, we derived the yearly probability of uptake using the number of hearing aids provided by the Chilean government to infants and children as well as the number of persons with hearing loss in those age groups (hearing aid uptake probability: 88%/year infants, 1.6%/year children age 1-4 years, 1.0%/year children age 5-18).10 For the Indian setting, we used a published estimate of 6% hearing aid use among children with hearing loss at age 12 to derive a hearing aid uptake probability of 1.0-1.5%/year.41 Lastly, for the Nigerian setting we used a published estimate of 5% hearing aid use at age 7 to derive a hearing aid uptake probability of 1.0-2.5%/year.42 We assumed a pediatric hearing aid discontinuation rate of 3%/year in all settings, and projected the yearly proportion of children ages 0-18 with aidable hearing loss (defined as PTA≥20 dB HL in the better ear) using hearing aids.43-45

To derive the yearly probability of cochlear implantation, we used DeciBHAI to estimate the number of children and adults with severe and profound hearing loss using hearing aids in each setting. We then scaled these estimates to the populations using age-specific population data.46 Incorporating the estimated number of yearly cochlear implants by setting (n=209 in Chile,51 n=2,000 in India,52 and n=5 in Nigeria48), we estimated the yearly probability of cochlear implant provision, given severe or greater hearing loss and hearing aid use, in each setting. We assumed a 1% annual probability of cochlear implant discontinuation in adults, and 1.5% per year in children.49-52

Statistical analysis (validation)

Our model inputs and outputs were reviewed by experts in the Lancet Commission on Hearing Loss, including experts in the Commission from Chile, India, and Nigeria. We validated across setting-specific epidemiologic and treatment estimates and describe the simulations for each validation run in the Results. Internal validation exercises were used to ensure that model-projected outputs sufficiently matched the published estimates used to derive model inputs. In addition to ensuring clinical and policy expert face validity of our modeling assumptions and results, we validated our model-projected outcomes to expected results quantitatively. We used coefficient of variance root mean square error (CV-RMSE) to compare model-projected outcomes with the published literature, and considered CV-RMSE≤15% to indicate adequate model fit.51,52 Additional detail on internal model validation exercises, including model code review, and examination of simulated patient trace files, can be found in the original DeciBHAI publication.5 Please see Appendix 1 for a table indicating the model input components and potential policy or program development implications associated with each outcome used in validation analysis.

Role of the funding source

This study was funded by the National Institute on Deafness and Other Communication Disorders and the National Institute on Aging (3UL1TR002553-0353 and F30 DC019846). The funding sources had no role in the design, analysis, or interpretation of the study or in the decision to submit the manuscript for publication. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. All authors had access to the dataset and shared the decision to submit for publication.

Results

Prevalence of sensorineural hearing loss by age and sex

Figure 1 presents the DeciBHAI-projected and GBD-estimated prevalence of SNHL across the lifespan, simulating persons from birth to death. The DeciBHAI-I projected age- and sex-specific prevalence of SNHL in Chile increased with age from 0.2% at age 1 year to 88.3% at age 87 years. The prevalence of SNHL likewise varied with age from 0.4% to 87.9% in India, and from 1.0% to 68.8% in Nigeria. A comparison of model-estimated and literature-based SNHL prevalence is presented in Figure 1. The CV-RMSE comparing GBD estimates to model-estimated SNHL prevalence were 6.0% (males) and 7.4% (females) in Chile, 5.6% and 5.4% in India, and 4.0% and 3.2% in Nigeria.

Progression of sensorineural hearing loss

When we incorporated an estimated 1.05 dB HL/year decline derived from longitudinal audiometric data for
the United States, we projected significantly more severe, profound, and complete hearing loss as a percent of all hearing loss compared to the GBD (Appendix 4). For the basecase analysis, we chose to incorporate the 1.05dB/year increase in dB HL due to several published longitudinal studies in high income settings finding similar results.22,53,54

Acute otitis media and chronic suppurative otitis media
Comparing the model-projected incidence of AOM at ages 0-90 years with published estimates, we achieved adequate fit across the three settings, with CV-RMSE ranging between 5.0-7.5%.24 The derived CSOM incidence rates produced an average yearly CSOM prevalence across all ages of 1.5% in Chile, 4.9% in India, and 3.4% in Nigeria, consistent with setting-specific estimates of CSOM prevalence.28

Prevalence of otitis media-related conductive hearing loss
The model-projected otitis media-related CHL, in cases/10,000 persons, ranged from 28.9-258.7 in India, 1.0-11.6 in Chile, and 11.3-111.1 in Nigeria (Table 2). The prevalence values were compared to those from a systematic review of global otitis media-associated CHL, with resulting CV-RMSE values all below 25%.24

Age-specific hearing aid use
For pediatric hearing aid use in all three settings, we simulated persons from birth through age 18 and recorded the hearing aid use prevalence among those with permanent hearing loss (SNHL or CHL without an acute infectious process) at each age. Hearing aid use prevalence at age 1 year was 50.0%, 1.3%, and 2.7% in Chile, India, and Nigeria respectively, and at age 18 was 8.9%, 6.4%, and 4.5%, respectively (Appendix 5).
We similarly validated age-specific hearing aid uptake probabilities for adults (Table 3). In Chile, we simulated persons aged 35 years until death, collecting the proportion of persons using hearing aids among those with hearing loss at age 65, 75, and 85 years. Including a delay-to-diagnosis factor, the model-projected outcomes were 3.2%, 7.9%, and 19.7%, respectively, and the CV-RMSE was 7.4%. None of the model-projected hearing aid use prevalence values in Chile were outside adjusted 95% confidence intervals from a Chilean national survey. For the Indian setting, the model-projected prevalence of hearing aid use among persons age 75 years with hearing loss >40 dB HL was 2.2%, comparable to an adjusted calibration target of 1.9% derived from the Indian National Disability Survey. In Nigeria, we assumed a low rate of hearing aid uptake throughout adulthood such that 1.1%, 0.9%, and 1.3% of simulated persons with hearing loss were using hearing aids at ages 65, 75, and 85 years, respectively.

### Table 3: Hearing loss cascade of care validation.

| Age | Chile, % of persons with hearing loss | India, % of persons with hearing loss >40 dB | Nigeria, % of persons with hearing loss |
|-----|-------------------------------------|-------------------------------------------|----------------------------------------|
|     | Model Outcome | Published Estimate (95% CI) | Model Outcome | Adjusted Published Estimate | Model Outcome | Estimate |
| 65  | 3.2 | 3.0 (1.3-4.8) | 1.4 | - | 1.1 | 0.5-1.0 |
| 75  | 7.9 | 6.9 (4.4-9.5) | 2.2 | 1.9$^*$ | 0.9 | 0.5-1.0 |
| 85  | 19.7 | 18.9 (13.9-24.0) | 2.3 | - | 1.3 | 0.5-1.0 |

$^*$ Age of reference population not stated, assumed to be 75 years. Published estimate adjusted by factor of 0.1 to reflect underestimation of hearing loss prevalence.

$^1$ Estimate range assumed based on expert opinion.

### Discussion

The efforts and results presented in this report extend DeciBHAL’s natural history framework of hearing loss prevention, natural history, diagnosis, and treatment to three international settings: Chile, India, and Nigeria. Model-projected results achieved reasonable fit to published estimates in validation exercises. We incorporated data from the GBD and high-quality systematic reviews or observational studies to inform hearing loss natural history inputs across both SNHL and CHL. Hearing aid and cochlear implantation were simulated as treatments for all causes of hearing loss, and we calibrated DeciBHAL treatment rates to current best estimates of coverage in the three settings.

DeciBHAL-I is the first validated decision model of hearing loss natural history and treatment throughout the lifespan in these settings. Because DeciBHAL simulates the current standards of care in Chile, India, and Nigeria, it provides a framework to be populated with
cost and utility data to estimate the economic efficiency of alternative hearing health scale-up strategies. Such estimates may be useful to finance ministers and health policy makers tasked with allocating limited resources to achieve maximum health utility benefit. Previously published decision models of hearing loss and its treatment in LMIC are limited in that those models consider single interventions only and do not allow for direct comparison of, for example, hearing screening at different ages.\(^5\) DeciBHAL simulates males and females across all ages and incorporates incident SNHL and CHL to allow for such direct comparisons and better inform hearing health policy. While input data, such as bilateral SNHL incidence, is occasionally collapsed across age groups, DeciBHAL is able to simulate outcomes for any user-determined age group (e.g., the under-5-year pediatric population).

Among the most significant differences between DeciBHAL across the settings is the epidemiology and etiology of hearing loss. In higher income settings, such as the United States and Chile, the majority of hearing loss is experienced later in life and is SNHL, whereas hearing loss in Nigeria and India occurs earlier in life and a higher proportion of hearing loss is otitis-media related CHL. At ages 55-64 years, there are a projected 7.6/10,000 cases of bilateral permanent hearing loss due to otitis-media in Chile, compared to 157.8/10,000 in India and 61.5/10,000 in Nigeria.\(^4\) These significant differences in hearing loss epidemiology suggest that the optimal allocation of treatment dollars to different hearing loss prevention and treatment programs are likely to differ among the settings. The ability of DeciBHAL to simulate CHL and its treatment is an advance over other simulation models and may inform optimal allocation through planned cost-effectiveness analyses.

Given the lack of longitudinal audiometric studies in Chile, India, and Nigeria, we incorporated data from high-income settings on the progression of SNHL. Across several studies and settings, SNHL progression converged around a 1dB/year increase in PTA dB HL.\(^24\) When incorporated into DeciBHAL-I, the projected proportions of persons with moderate, severe, and profound hearing loss were higher than GBD estimates.\(^25\) While DeciBHAL has a calibration factor to allow for slowing the rate of SNHL decline, in our base-case analysis we did not adjust to GBD data. This decision was based on: 1) agreement among our clinical collaborators that the rate of hearing loss progression would not be slower in Chile, India, and Nigeria compared to the US and Australia, and 2) emerging data suggesting that hearing loss may be more severe in low- and middle-income settings than previously thought. Future analyses might calibrate hearing loss severity to better match GBD data in sensitivity analyses, or to setting-specific longitudinal studies as they become available.

We incorporated setting-specific estimates of hearing aid and cochlear implant uptake to simulate the hearing cascade of care in Chile, India, and Nigeria. In Chile, we were able to incorporate data from the Ministry of Health reporting the number of pediatric and adult hearing aids provided each year and validate to a nationally representative survey of hearing aid use. In India, we did not have estimates of adult hearing aid uptake and thus calibrated the yearly probability of hearing aid uptake to results from a National Disability survey in that country. We were unable to identify any nationally representative estimates of adult hearing aid use in Nigeria, so we relied on expert opinion to adjust published rates of hearing aid uptake among persons who acquired hospital-based otolaryngologic care. As the true rates of current hearing aid uptake is uncertain, especially in India and even more so in Nigeria, this parameter should be explored in sensitivity analyses.

DeciBHAL is purposefully setting-specific to allow for high-quality estimations of hearing healthcare policy effects in Chile, India, and Nigeria. These locations were chosen due to data availability but also differences in region, income-level, and hearing loss epidemiology and treatment. Results of future and planned cost-effectiveness analyses set in Chile, India, and Nigeria may be generalizable to other settings with similar epidemiologic and demographic characteristics. However, the results will likely not be generalizable to many settings and other methods will be required to apply DeciBHAL results outside of its validated settings. As most published model-based analyses are in high-income settings, there is a great need for modeling frameworks in low- and middle-income settings. One option would be to create an openly available web-based model version that would allow entries of country- or region-specific input values to tailor results. While a fully validated model in another setting would require identification and derivation of all setting-specific inputs listed in Table 1, future research might clarify a subset of these inputs that are most influential and could be tailorable in a web-based version of DeciBHAL.

The extended model DeciBHAL-I has several limitations, primarily related to assumptions made in the absence of high quality, setting-specific data. We worked with clinical and policy stakeholders to simplify the complex natural history and treatment of hearing loss across the lifespan to allow for feasible creation of a policy decision model. DeciBHAL is populated with high quality setting-specific estimates of hearing loss acquisition, progression, and treatment; however, there were data limitations, especially pertaining to treatment uptake in India and Nigeria, that required model calibration based on expert opinion. In some cases, we incorporated data from high-income settings such as the United States when we were unable to find similar setting-specific estimates. We were also unable in the current model version to include distributions around all input parameters (as would be necessary to compute 95% confidence intervals around model-projected
outcomes) due to data limitations. In all cases, the impact of these uncertain estimates should be explored in sensitivity analyses in studies using DeciBHAL. Additionally, there is a lack of robust epidemiologic data on cause-specific contributors to SNHL. DeciBHAL includes meningitis and ototoxicity as explicit causes of SNHL. However, the epidemiologic data to inform estimates of the proportion of SNHL due to ototoxicity are currently under investigation and future model versions should incorporate this factor. We were unable to attain the target CV-RMSE value of ≤15% for the calibration of the prevalence of otitis media-related CHL in Chile. Our model-projected prevalence estimates were all within 2-3/10,000 of the target, but given the low absolute numbers of people with otitis media-related CHL in Chile, we were unable to attain a CV-RMSE ≤15%. Lastly, persons in DeciBHAL-I are assigned an SNHL PTA severity of 25 dB HL upon acquiring age-related and other hearing loss. This is different than the minimum PTA threshold suggested by the WHO of 20 dB HL and the effects of assigning persons a threshold of 20 dB HL at SNHL onset should be explored in future sensitivity analysis.

We find that DeciBHAL-I reasonably simulates hearing loss prevention, natural history, diagnosis, and treatment in Chile, India, and Nigeria. As policymakers worldwide prioritize scarce resource allocation across hearing and other health policies, DeciBHAL may provide setting-specific estimates to guide optimal allocation.

Contributors
Conceptualization: EDB, AA, CD, OO, GDS
Methodology: EDB, OO, GDS
Software: EDB, AA, SD, MS, OO, GDS
Validation: All authors
Formal analysis: EDB, AA, SD, MS, OO, GDS
Investigation: EDB, AA, SD, MS, OO, GDS
Resources: OO, GDS
Data curation: EDB, AA, SD, MS, OO, GDS
Writing - original draft: EDB, AA, GDS
Writing - review & editing: All authors
Visualization: EDB, AA, SD, MS, OO, GDS
Supervision: OO, GDS
Funding Acquisition: EDB, OO, GDS

Data sharing statement
Model code and input data may be requested from the corresponding author.

Declaration of interests
The authors have no conflicts of interest to declare.

Funding
This study was funded by the National Institute on Deafness and Other Communication Disorders and the National Institute on Aging (3UL1-TR00253-03S3 and F30 DC019846). The funding sources had no role in the design, analysis, or interpretation of the study or in the decision to submit the manuscript for publication. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

References
1. Wilson BS, Tucci DL, Merson MH, O’Donoghue GM. Global hearing health care: new findings and perspectives. Lancet North Am Ed. 2017;390(10115):2503–2515.
2. World Health Organization. World report on hearing. Geneva 2021. Accessed 21 May 2021 at: https://www.who.int/publications/i/item/world-report-on-hearing.
3. Olusany B, Neumann K, Saunders E. The global burden of disabling hearing impairment: a call to action. Bull World Health Organ. 2014;92:167–173.
4. Borre ED, Diab MM, Ayer A, et al. Evidence gaps in economic analyses of hearing healthcare: a systematic review. EClinicalMedicine. 2021;35: 100872.
5. Borre ED, Myers ER, Dubno JR, et al. Development and validation of DeciBHAL-USA: a novel microsimulation model of hearing loss across the lifespan in the United States. EClinicalMedicine. 2022;44:101268.
6. Kemper AR, Downs SM. A cost-effectiveness analysis of newborn hearing screening strategies. Arch Pediatr Adolesc Med. 2000;154 (9):484–488.
7. Keren R, Helfand M, Honder C, McPhillis H, Lieu TA. Projected cost-effectiveness of statewide universal newborn hearing screening. Pediatrics. 2002;109(5):855–864.
8. Wilson BS, Tucci DL, O’Donoghue GM, Merson MH, Frankish H. A Lancet Commission to address the global burden of hearing loss. Lancet North Am Ed. 2019;393(10186):2106–2108.
9. Vemer P, Ramos IC, Van Voorn G, Al M, Fernstra T. AdVISH: a validation-assessment tool of health-economic models for decision makers and model users. PharmacoEconomics. 2016;34(4):349–361.
10. Halie LM, Kamenov K, Bryant PS, et al. Hearing loss prevalence and years lived with disability, 1990–2019: findings from the Global Burden of Disease Study 2019. Lancet North Am Ed. 2021;397(10278):996–1009.
11. World Health Organization. Global health observatory data repository: life tables by country. Accessed 20 January 2022 at: https://apps.who.int/gho/data/view.main.LT62010?lang=en.
12. United Nations department of economic and social affairs: world population prospects 2019 mortality data. Accessed 20 January 2022 at: https://population.un.org/wpp/Download/Standard/Mortality/.
13. GBD Results Tool. 2022. https://ghdx.healthdata.org/gbd-results-tool2022.
14. Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. Lancet Infect Dis. 2016;10(3):317–328.
15. Global, regional, and national burden of meningitis, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Glob Health. 2018;6(12):e1061–e1082.
16. Thigpen MC, Whitney CG, Messonnier NE, et al. Bacterial meningitis in the United States, 1998-2007. N Engl J Med. 2011;364(21):2016–2025.
17. Soetens HM, Diao EO, Bicaba BW, et al. Bacterial meningitis epidemiology in five countries in the meningitis belt of sub-Saharan Africa, 2015-2017. J Infect Dis. 2020;220(2 Suppl 4):S169–S174.
18. Rodenhurst Vlot MB, Ruytens I, Oostenhink R, Goedegebure A, van der Schoof MP. Systematic review: incidence and course of hearing loss caused by bacterial meningitis: in search of an optimal timed audiological follow-up. Otol Neurotol. 2016;37(1):1–8.
19. Dillard LK, Martinez RX, Perez LL, Fullerton AM, Chadha S, Donoghue GM. Global hear-
